View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings assigns B1 rating to Blackstone Mortgage Trust, Inc.'s...

Moody's Ratings (Moody's) has assigned a B1 rating to Blackstone Mortgage Trust, Inc.'s (BXMT) $450 million of senior secured notes due 2029. BXMT's B1 corporate family rating (CFR) and existing B1 senior secured notes and senior secured bank credit facility ratings were unaffected by this transacti...

 PRESS RELEASE

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Off...

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu thereof) and warrant...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 23, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Eyenovia Provides Update on Restructuring Efforts

Eyenovia Provides Update on Restructuring Efforts Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives to maximize stakeholder value NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today provided an update on its ongoing restructuring efforts. The Company announced today that Avenue Capital Management L.P. has agreed to support a potential restructuring of Eyenovia’s Loan a...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

The Dow Chemical Company - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

 PRESS RELEASE

Eyenovia Provides Update on Phase 3 CHAPERONE Study

Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and evaluate next steps for the program NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that a review of the CHAPERONE data by an independent Data Review Committee (DRC) found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in vis...

 PRESS RELEASE

Spero Therapeutics Announces Third Quarter 2024 Operating Results and ...

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter e...

Dow Chemical Company (The): Lackluster demand slows earnings recovery

Our credit view of this issuer reflects its long term feedstock advantage in the Americas and currently elevated debt leverage due to slow demand recovery.

 PRESS RELEASE

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Cor...

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery Appointed Andrew Jones as Chief Financial Officer Company to host conference call and w...

 PRESS RELEASE

Spero Therapeutics to Report Third Quarter 2024 Financial Results and ...

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to...

 PRESS RELEASE

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12t...

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host ...

 PRESS RELEASE

Sun Communities, Inc. Announces Restructuring and CEO Retirement

Sun Communities, Inc. Announces Restructuring and CEO Retirement Implementing Comprehensive Restructuring and Cost Cutting Plan Expected to Save $15 - $20 million annually; John McLaren to Return to Company as President; CEO Gary Shiffman to Retire in 2025 Southfield, MI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust ("REIT") that owns and operates, or has an interest in, manufactured housing (“MH”) and recreational vehicle (“RV”) communities and marinas, today provided the following update: Restructuring an...

 PRESS RELEASE

Sun Communities Reports Results for the Third Quarter and First Nine M...

Sun Communities Reports Results for the Third Quarter and First Nine Months of 2024       Net Income per Diluted Share of $2.31 for the Quarter Core FFO per Share of $2.34 for the Quarter       North America Same Property NOI increased by 0.5% for the Quarter and 3.6% for the First Nine Months of 2024 versus corresponding 2023 Periods North America Same Property Adjusted Blended Occupancy for MH and RV of 98.8% represents a 160 basis point year-over-year increase       Revising Full-Year Core FFO per Share Guidance for 2024 to $6.76 - $6.84 Revising Full-Year North ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 2, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provi...

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients Phase 3 PIVOT-PO trial of tebipenem HBr remains on track for enrollment completion in 2H 2025 Cash runway extended into mid-2026 following a reduction in workforce and restructuring of operations; Unaudited Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- ...

Moody's Ratings has changed The Dow Chemical Company's outlook to nega...

Moody's Ratings (Moody's) has changed the rating outlook on The Dow Chemical Company ("Dow") to negative from stable. At the same time, we have affirmed Dow's Baa1 senior unsecured credit rating and Prime-2 short term rating for commercial paper. The negative outlook is driven by a slow recovery i...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 26, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 25, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Sun Communities, Inc. Announces Date for Third Quarter 2024 Earnings R...

Sun Communities, Inc. Announces Date for Third Quarter 2024 Earnings Release and Conference Call Southfield, MI, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust ("REIT") that owns and operates, or has an interest in, manufactured housing (“MH”) and recreational vehicle (“RV”) communities and marinas, announces it will release third quarter 2024 operating results after the market closes on Wednesday, November 6, 2024. The Company will host a conference call to discuss these results on Wednesday, November 6, 2024, at 5:00 P...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch